Analysis of national external quality assessment results for transfusion compatibility test, 2018 to 2023
10.13303/j.cjbt.issn.1004-549x.2025.12.011
- VernacularTitle:2018—2023年全国临床输血相容性检测室间质量评价结果分析
- Author:
Junhua HU
1
;
Peng ZHANG
1
;
Jiali LIU
2
;
Zhiguo WANG
2
;
Yanming LIU
1
;
Shengchen TIAN
1
;
Wanru MA
1
;
Xiang LI
1
;
Xuebin ZHAO
1
;
Feng XUE
1
;
Yuntian WANG
1
;
Dong LIN
1
;
Zheng SUN
1
;
Jiwu GONG
1
;
Lin ZHOU
3
Author Information
1. Department of Blood Transfusion, Beijing Hospital, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, National Center of Gerontology, Beijing 100730, China
2. National Center for Clinical Laboratories/Beijing Engineering Research Center of Laboratory Medicine, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology, Beijing 100730, China
3. School of Materials and Chemical Engineering, Bengbu University, Bengbu 233030, China
- Publication Type:Journal Article
- Keywords:
transfusion compatibility test;
external quality assessment;
quality control;
competency test
- From:
Chinese Journal of Blood Transfusion
2025;38(12):1720-1727
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To analyze the results of national external quality assessment (EQA) for transfusion compatibility test from 2018 to 2023, with the aim of providing references for improving laboratory testing quality and ensuring the safety of clinical blood transfusion. Methods: Three EQA programs were conducted annually, each distributing 22 quality assessment samples. Participating transfusion laboratories were required to complete testing within specified deadlines and to submit results along with documentation of testing methodologies, reagents, and equipment used. National Center for Clinical Laboratories (NCCL) conducted statistical analysis of laboratory results, evaluated testing outcomes and related circumstances, and provided feedback to participating laboratories. EQA data from transfusion laboratories across China from 2018 to 2023 were collected and systematically analyzed. Results: From 2018 to 2023, the qualification rates for all five items (ABO forward typing, ABO reverse typing, Rh blood group typing, antibody screening, and cross-matching) were 67.59%, 77.11%, 77.38%, 72.78%, 79.96%, and 85.16%, respectively. The mean qualification rates for ABO forward typing, ABO reverse typing, RhD blood group typing, antibody screening, and cross-matching over the past six years were 96.25%±0.59%, 90.45%±4.52%, 96.05%±0.71%, 90.88%±2.86%, and 88.34%±3.48%, respectively. The qualification rates in 2019, 2020, 2022, and 2023 all showed a stable trend of "blood stations>tertiary hospitals>secondary hospitals". The mean qualification rate of laboratories in secondary hospitals from 2018 to 2023 was significantly lower than those of laboratories in tertiary hospitals and blood stations (P<0.05), while no significant difference was observed between laboratories in tertiary hospitals and blood stations (P>0.05). The micro column agglutination method was the most widely used in all five tests. In the four test items, namely ABO forward typing, ABO reverse typing, antibody screening, and cross-matching, there was a statistically significant difference in the qualification rate of micro column agglutination method compared to other methods (P<0.05). There was a statistical difference in the qualification rate between manual and automated detection using micro column agglutination method in the cross-matching tests (P<0.05), whereas no significant difference was noted for the other test items (P>0.05). Conclusion: From 2018 to 2023, the number of laboratories participating in EQA activities has been increasing year by year, and the qualification rate has shown an overall upward trend. The type of laboratory is a key factor affecting the qualification rate, and the testing capabilities of some laboratories still need to be improved. The micro column agglutination method is widely used in transfusion compatibility tests. The established EQA program effectively monitors quality issues in laboratories, drives continuous improvement, and ensures sustained enhancement of testing standards to safeguard clinical blood safety.
